AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29747957 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 52
Study 27759633 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block
Number of subjects: 60
Study 27759633 — intervention group
Group type: COMPARATOR
Intervention: Continuous fascia iliaca compartment block
Number of subjects: 60
Study 24800966 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based guided self-help course (Happy@Work), 6 weekly lessons
Number of subjects: 231
Study 24800966 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 231
Study 22418581 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated EVD catheters
Number of subjects: 434
Study 22418581 — intervention group
Group type: COMPARATOR
Intervention: Standard EVD catheters
Number of subjects: 434
Study 20598573 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal valve polyurethane PICC
Number of subjects: 326
Study 20598573 — intervention group
Group type: COMPARATOR
Intervention: Distal valve silicone PICC
Number of subjects: 326
Study 18665068 — intervention group
Group type: COMPARATOR
Intervention: $20 check incentive
Number of subjects: 578
Study 18665068 — intervention group
Group type: EXPERIMENTAL
Intervention: $50 check incentive
Number of subjects: 578
Study 15590212 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol therapy (50 microg per day) for 3 months
Number of subjects: 59
Study 15590212 — intervention group
Group type: COMPARATOR
Intervention: Untreated arm
Number of subjects: 59
Study 12895191 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg
Number of subjects: 24
Study 12895191 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg
Number of subjects: 24
Study 12895191 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 24
Study 10100650 — intervention group
Group type: EXPERIMENTAL
Intervention: Single treatment IPL
Number of subjects: 71
Study 10100650 — intervention group
Group type: EXPERIMENTAL
Intervention: Double treatment IPL
Number of subjects: 71
Study 8728345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of mycophenolate mofetil (1.5 g)
Number of subjects: 12
Study 8728345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of mycophenolate mofetil (1.5 g)
Number of subjects: 12
Study 8728345 — intervention group
Group type: COMPARATOR
Intervention: Both routes (oral and intravenous)
Number of subjects: 12
Study 2059780 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate (Kaltostat) dressing
Number of subjects: 46
Study 2059780 — intervention group
Group type: COMPARATOR
Intervention: Scarlet red dressing
Number of subjects: 46
Study 6344625 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg acetaminophen
Number of subjects: 269
Study 6344625 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg aspirin
Number of subjects: 269
Study 6344625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 31945052 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cultures taken
Number of subjects: 2392
Study 31945052 — intervention group
Group type: COMPARATOR
Intervention: Missing blood cultures
Number of subjects: 2392
Study 31184740 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute SBT with 8-cm H2O pressure support ventilation (n=557)
Number of subjects: 1153
Study 31184740 — intervention group
Group type: COMPARATOR
Intervention: 2-hour T-piece SBT (n=578)
Number of subjects: 1153
Study 31184740 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute SBT with 8-cm H2O pressure support ventilation
Number of subjects: 1153
Study 31184740 — intervention group
Group type: COMPARATOR
Intervention: 2-hour T-piece SBT
Number of subjects: 1153
Study 29020251 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (100-200 mg bid)
Number of subjects: 444
Study 29020251 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (600-800 mg tid)
Number of subjects: 444
Study 29020251 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (375-500 mg bid)
Number of subjects: 444
Study 26895675 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of mesenteric defects
Number of subjects: 2507
Study 26895675 — intervention group
Group type: COMPARATOR
Intervention: Non-closure of mesenteric defects
Number of subjects: 2507
Study 23932566 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute educational intervention
Number of subjects: 479
Study 23067154 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintended pregnancies
Number of subjects: 1264
Study 23067154 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortions among unintended pregnancies
Number of subjects: 1264
Study 23067154 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortions among all pregnancies
Number of subjects: 1264
Study 23067154 — intervention group
Group type: EXPERIMENTAL
Intervention: Age less than 35 years
Number of subjects: 1264
Study 23067154 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than high school education
Number of subjects: 1264
Study 23067154 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployed
Number of subjects: 1264
Study 23067154 — intervention group
Group type: EXPERIMENTAL
Intervention: More than three children
Number of subjects: 1264
Study 23067154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower income
Number of subjects: 1264
Study 23067154 — intervention group
Group type: EXPERIMENTAL
Intervention: More than three children among women with unintended pregnancy
Number of subjects: 1264
Study 23067154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower income among women with unintended pregnancy
Number of subjects: 1264
Study 23067154 — intervention group
Group type: EXPERIMENTAL
Intervention: Age less than 35 years among women with unintended pregnancy
Number of subjects: 1264
Study 19950736 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent skin patches (two adhesive electrodes)
Number of subjects: 28
Study 19950736 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion with fentanyl (Control Group)
Number of subjects: 28
Study 17518957 — intervention group
Group type: EXPERIMENTAL
Intervention: Profylin fluoride gel with buffering components
Number of subjects: 14
Study 17518957 — intervention group
Group type: EXPERIMENTAL
Intervention: Profylin fluoride gel without buffering components
Number of subjects: 14
Study 17518957 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing with water
Number of subjects: 14
Study 12695250 — intervention group
Group type: EXPERIMENTAL
Intervention: NEI‐VFQ overall score and subscale scores (near activities, dependency, driving, role difficulties, distance activities, mental health, general vision, peripheral vision, and social functioning)
Number of subjects: 218
Study 10443767 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1141
Study 10443767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1141
Study 8777886 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet-Cutter
Number of subjects: 60
Study 8777886 — intervention group
Group type: COMPARATOR
Intervention: CUSA
Number of subjects: 60
Study 8777886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 60
Study 1671885 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 3161
Study 1671885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3161
Study 6630552 — intervention group
Group type: EXPERIMENTAL
Intervention: WAIS
Number of subjects: 88
Study 6630552 — intervention group
Group type: COMPARATOR
Intervention: WAIS-R
Number of subjects: 88
Study 31177761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization methods applied to blood metabolites
Number of subjects: 0
Study 31177761 — intervention group
Group type: EXPERIMENTAL
Intervention: Three methods of Mendelian randomization
Number of subjects: 0
Study 27618821 — intervention group
Group type: EXPERIMENTAL
Intervention: Genexol-PM 260 mg/m2
Number of subjects: 212
Study 27618821 — intervention group
Group type: COMPARATOR
Intervention: Genexol 175 mg/m2
Number of subjects: 212
Study 27618821 — intervention group
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Number of subjects: 212
Study 27618821 — intervention group
Group type: COMPARATOR
Intervention: Genexol
Number of subjects: 212
Study 25839363 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education materials (leaflet and video)
Number of subjects: 40
Study 25839363 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication resource for physicians
Number of subjects: 40
Study 25839363 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life survey
Number of subjects: 40
Study 23890047 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening administration of low-dose aspirin
Number of subjects: 258
Study 21773673 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% fixed combination (TTFC)
Number of subjects: 105
Study 19384192 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ (160 mg/25 mg, titrated to 320/25 mg)
Number of subjects: 482
Study 19384192 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine/HCTZ (5 mg/25 mg, titrated to 10/25 mg)
Number of subjects: 482
Study 17107398 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (LGG) 10 x 10^9 colony-forming units daily for 8 weeks
Number of subjects: 54
Study 17107398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15902479 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain clamped for 1 hour postoperatively, then kept open for 48 hours.
Number of subjects: 73
Study 15902479 — intervention group
Group type: COMPARATOR
Intervention: Drain clamped and released for 10 min every 2 hours for 24 hours.
Number of subjects: 73
Study 15902479 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 15902479 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hourly clamping of drain and release for 10 min
Number of subjects: 73
Study 10687944 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg PPA
Number of subjects: 15
Study 10687944 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg PPA
Number of subjects: 15
Study 10687944 — intervention group
Group type: COMPARATOR
Intervention: Oxymetazoline nasal spray
Number of subjects: 15
Study 10687944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10687944 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA (both doses)
Number of subjects: 15
Study 8678175 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2 challenge
Number of subjects: 203
Study 8678175 — intervention group
Group type: COMPARATOR
Intervention: No reaction to 35% CO2 challenge
Number of subjects: 203
Study 1884574 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash
Number of subjects: 15
Study 1884574 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenolic mouthwash
Number of subjects: 15
Study 1884574 — intervention group
Group type: COMPARATOR
Intervention: Saline mouthwash
Number of subjects: 15
Study 6130599 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid tablets (total acid‐neutralizing capacity, 280 mmol/day)
Number of subjects: 75
Study 6130599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 6130599 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid tablets
Number of subjects: 75
Study 6130599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 75
Study 6130599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 75
Study 30343455 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 134
Study 30343455 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving therapy (PST)
Number of subjects: 134
Study 30343455 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief supportive psychotherapy (BSP)
Number of subjects: 134
Study 30343455 — intervention group
Group type: COMPARATOR
Intervention: All three therapies
Number of subjects: 134
Study 29974934 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 17
Study 29974934 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 26717498 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobilization
Number of subjects: 80
Study 26717498 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar massage
Number of subjects: 80
Study 26717498 — intervention group
Group type: EXPERIMENTAL
Intervention: Triceps surae stretching
Number of subjects: 80
Study 26717498 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 24411921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib 300 mg orally twice daily on days 1‐21
Number of subjects: 348
Study 24411921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib 600 mg orally twice daily on days 1‐21
Number of subjects: 348
Study 24411921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib 300 mg orally twice daily on days 1‐7 and 15‐21
Number of subjects: 348
Study 24411921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib 600 mg orally twice daily on days 1‐7 and 15‐21
Number of subjects: 348
Study 23160054 — intervention group
Group type: EXPERIMENTAL
Intervention: School Well-Being Therapy intervention
Number of subjects: 227
Study 23160054 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo
Number of subjects: 227
Study 20147473 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT:FO
Number of subjects: 12
Study 20147473 — intervention group
Group type: COMPARATOR
Intervention: MCT:LCT
Number of subjects: 12
Study 18510278 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased inspections and surveillance activities (over 350 inspections/year in 250 sites/year)
Number of subjects: 600
Study 18510278 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of prevention strategies and monitoring of notifications and certificates of work-related injuries
Number of subjects: 600
Study 18510278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanctions related to high-level work, scaffolding, protection against falls from heights, and Personal Protective Equipment (DPI)
Number of subjects: 600
Study 15713438 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorinated solution of neutral red with ultraviolet-A light exposure
Number of subjects: 0
Study 12589898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study 12589898 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatments for prodromal symptoms
Number of subjects: 0
Study 12589898 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11149790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg) preoperatively
Number of subjects: 55
Study 11149790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg) postoperatively
Number of subjects: 55
Study 11149790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 55
Study 11149790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg) preoperatively or postoperatively
Number of subjects: 55
Study 7488578 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon green laser photocoagulation
Number of subjects: 20
Study 7488578 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 20
Study 2024569 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chest physiotherapy alone (PHYS)
Number of subjects: 51
Study 2024569 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy and positive expiratory pressure (PEP)
Number of subjects: 51
Study 2024569 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy with both positive expiratory pressure and inspiratory resistance (RMT)
Number of subjects: 51
Study 30715452 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of AS04-adjuvanted HPV-16/18 vaccine
Number of subjects: 0
Study 30715452 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of AS04-adjuvanted HPV-16/18 vaccine
Number of subjects: 0
Study 27757820 — intervention group
Group type: EXPERIMENTAL
Intervention: REHACOP group (cognitive rehabilitation)
Number of subjects: 44
Study 27757820 — intervention group
Group type: COMPARATOR
Intervention: Control group (occupational therapy)
Number of subjects: 44
Study 25308787 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly induction with intravitreal bevacizumab (every 2 weeks for 3 consecutive injections)
Number of subjects: 90
Study 25308787 — intervention group
Group type: COMPARATOR
Intervention: Monthly induction with intravitreal bevacizumab (every 4 weeks for 3 consecutive injections)
Number of subjects: 90
Study 25308787 — intervention group
Group type: COMPARATOR
Intervention: Immediate pro re nata (prn) after the first injection
Number of subjects: 90
Study 24180715 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) using propofol plus remifentanil
Number of subjects: 50
Study 24180715 — intervention group
Group type: COMPARATOR
Intervention: Volatile induction/maintenance of anaesthesia (VIMA) using sevoflurane
Number of subjects: 50
Study 21694537 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U lipase/kg/meal
Number of subjects: 16
Study 21694537 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 U lipase/kg/meal
Number of subjects: 16
Study 21694537 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 U lipase/kg/meal
Number of subjects: 16
Study 21694537 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 U lipase/kg/meal
Number of subjects: 16
Study 21694537 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 16
Study 19023899 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled maintenance therapy (group A) - IFX every 2 months
Number of subjects: 40
Study 19023899 — intervention group
Group type: COMPARATOR
Intervention: On demand maintenance therapy (group B) - IFX on relapse
Number of subjects: 40
Study 17534584 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced normothermia (IN) with automated surface cooling system
Number of subjects: 24
Study 17534584 — intervention group
Group type: COMPARATOR
Intervention: Non-shivering patients
Number of subjects: 24
Study 15037323 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (400 mg)
Number of subjects: 12
Study 15037323 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 12
Study 11442611 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed alexandrite laser (755 nm, 2‐msec pulse, 10 mm spot) at 25 J/cm2 or 40 J/cm2
Number of subjects: 20
Study 11442611 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed diode laser (800 nm, 12.5 msec or 25 msec, 9 mm spot) at 25 J/cm2 or 40 J/cm2
Number of subjects: 20
Study 11442611 — intervention group
Group type: COMPARATOR
Intervention: Long-pulsed diode laser at 40 J/cm2
Number of subjects: 20
Study 11442611 — intervention group
Group type: COMPARATOR
Intervention: Long-pulsed alexandrite laser
Number of subjects: 20
Study 9929929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with increased omega-3 PUFA in addition to ibuprofen treatment
Number of subjects: 23
Study 9929929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no omega-3 PUFA diet, only ibuprofen)
Number of subjects: 23
Study 8306366 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2 i.a. infusion for 4 days (Group A, n = 3)
Number of subjects: 11
Study 8306366 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha s.c. for 5 days followed by continuous IL‐2 i.v. infusion for 5 days (Group B, n = 4)
Number of subjects: 11
Study 8306366 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2 i.v. infusion for 4 days with s.c. IFN alpha on days 1 and 4 (Group C, n = 4)
Number of subjects: 11
Study 3378553 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulphate 1.25 micrograms kg‐1
Number of subjects: 40
Study 3378553 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.75 micrograms kg‐1
Number of subjects: 40
Study 3378553 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulphate 2.5, 2.5 and 5 micrograms kg‐1
Number of subjects: 40
Study 3378553 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 1.5, 1.5 and 3.0 micrograms kg‐1
Number of subjects: 40
Study 3378553 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulphate (same dose as Group 2)
Number of subjects: 40
Study 3378553 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (same dose as Group 2)
Number of subjects: 40
Study 30557034 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 60
Study 30557034 — intervention group
Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 60
Study 27922270 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioral intervention
Number of subjects: 407
Study 27922270 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control
Number of subjects: 407
Study 26698303 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU ergocalciferol daily until delivery
Number of subjects: 180
Study 26698303 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral bolus of 200,000 IU cholecalciferol
Number of subjects: 180
Study 26698303 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Vitamin D)
Number of subjects: 180
Study 24025658 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare Part D prescription drug plan (PDP) with covered drugs
Number of subjects: 0
Study 24025658 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare Part D prescription drug plan (PDP) with noncovered drugs
Number of subjects: 0
Study 24025658 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior authorization or step therapy for covered drugs
Number of subjects: 0
Study 24025658 — intervention group
Group type: COMPARATOR
Intervention: Medicare Part D prescription drug plan (PDP)
Number of subjects: 0
Study 20422423 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μg misoprostol orally
Number of subjects: 658
Study 20422423 — intervention group
Group type: COMPARATOR
Intervention: 600 μg misoprostol rectally
Number of subjects: 658